Invited Talks

Speaker

2020 – A novel rapid zebrafish model for validation of potential therapies for fatal pediatric brain tumors, 2020 AACR Annual Meeting, Virtual

2019 – Validation of potential therapies for treatment of fatal pediatric brain tumors DIPG and AT/RT using a novel rapid intracranial model in zebrafish, Lightning Lecture, AACR Special Conference on Advances in Pediatric Cancer Research,  Montreal, Quebec, Canada

2019 – Targeting lethal high grade gliomas and DIPG with the DNA binding agent Quinacrine, SNO Pediatric Neuro-Oncology Basic and Translational Research Conference, San Francisco

2016 – Disrupting the epigenetic modifier HMGA2 in lethal pediatric and adult gliomas inhibits invasion, growth and tumorigenicity, 2016 SNO Annual Meeting (Selected as SNO “Highlight of the Day”), Scottsdale, Arizona

2016 – Targeting the stem-cell factor HMGA2 in lethal brain tumors DIPG and glioblastoma increases apoptosis and inhibits invasion, growth and tumorigenicity, 2016 Neuro Tumor Club
Dinner Meeting at AACR, New Orleans, Louisiana

2015 – Disrupting the epigenetic modifier HMGA2 in DIPG and its therapeutic implications. Bi-Annual Meeting of Mid-Atlantic DIPG Consortium Meeting, National Cancer Institute (NCI), Bethesda, Maryland

2015 – Disrupting the epigenetic modifier HMGA2 in DIPG and GBM inhibits tumor invasion, growth and tumorigenicity. Grand Rounds, The Johns Hopkins University, Department of Pathology, Baltimore, Maryland

2015 – Disrupting the epigenetic modifier HMGA2 in DIPG and GBM inhibits tumor invasion, growth and tumorigenicity. SNO Pediatric Neuro-Oncology Basic and Translational Research Conference , San Diego, California